129 related articles for article (PubMed ID: 38385325)
21. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
[TBL] [Abstract][Full Text] [Related]
22. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.
Ho HK; Pok S; Streit S; Ruhe JE; Hart S; Lim KS; Loo HL; Aung MO; Lim SG; Ullrich A
J Hepatol; 2009 Jan; 50(1):118-27. PubMed ID: 19008009
[TBL] [Abstract][Full Text] [Related]
23. H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma.
Joshi JJ; Coffey H; Corcoran E; Tsai J; Huang CL; Ichikawa K; Prajapati S; Hao MH; Bailey S; Wu J; Rimkunas V; Karr C; Subramanian V; Kumar P; MacKenzie C; Hurley R; Satoh T; Yu K; Park E; Rioux N; Kim A; Lai WG; Yu L; Zhu P; Buonamici S; Larsen N; Fekkes P; Wang J; Warmuth M; Reynolds DJ; Smith PG; Selvaraj A
Cancer Res; 2017 Dec; 77(24):6999-7013. PubMed ID: 29247039
[TBL] [Abstract][Full Text] [Related]
24. Discovery of 1,6-Naphthyridin-2(1
Zhang X; Wang Y; Ji J; Si D; Bao X; Yu Z; Zhu Y; Zhao L; Li W; Liu J
J Med Chem; 2022 Jun; 65(11):7595-7618. PubMed ID: 35635004
[TBL] [Abstract][Full Text] [Related]
25. FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.
Weiss A; Adler F; Buhles A; Stamm C; Fairhurst RA; Kiffe M; Sterker D; Centeleghe M; Wartmann M; Kinyamu-Akunda J; Schadt HS; Couttet P; Wolf A; Wang Y; Barzaghi-Rinaudo P; Murakami M; Kauffmann A; Knoepfel T; Buschmann N; Leblanc C; Mah R; Furet P; Blank J; Hofmann F; Sellers WR; Graus Porta D
Mol Cancer Ther; 2019 Dec; 18(12):2194-2206. PubMed ID: 31409633
[TBL] [Abstract][Full Text] [Related]
26. Discovery of Novel 7-Azaindole Derivatives as Selective Covalent Fibroblast Growth Factor Receptor 4 Inhibitors for the Treatment of Hepatocellular Carcinoma.
Zhong Z; Shi L; Fu T; Huang J; Pan Z
J Med Chem; 2022 May; 65(10):7278-7295. PubMed ID: 35549181
[TBL] [Abstract][Full Text] [Related]
27. First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.
Kim RD; Sarker D; Meyer T; Yau T; Macarulla T; Park JW; Choo SP; Hollebecque A; Sung MW; Lim HY; Mazzaferro V; Trojan J; Zhu AX; Yoon JH; Sharma S; Lin ZZ; Chan SL; Faivre S; Feun LG; Yen CJ; Dufour JF; Palmer DH; Llovet JM; Manoogian M; Tugnait M; Stransky N; Hagel M; Kohl NE; Lengauer C; Sherwin CA; Schmidt-Kittler O; Hoeflich KP; Shi H; Wolf BB; Kang YK
Cancer Discov; 2019 Dec; 9(12):1696-1707. PubMed ID: 31575541
[TBL] [Abstract][Full Text] [Related]
28. Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.
Lu X; Chen H; Patterson AV; Smaill JB; Ding K
J Med Chem; 2019 Mar; 62(6):2905-2915. PubMed ID: 30403487
[TBL] [Abstract][Full Text] [Related]
29. FGF19 Protects Hepatocellular Carcinoma Cells against Endoplasmic Reticulum Stress via Activation of FGFR4-GSK3β-Nrf2 Signaling.
Teng Y; Zhao H; Gao L; Zhang W; Shull AY; Shay C
Cancer Res; 2017 Nov; 77(22):6215-6225. PubMed ID: 28951455
[TBL] [Abstract][Full Text] [Related]
30. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models.
French DM; Lin BC; Wang M; Adams C; Shek T; Hötzel K; Bolon B; Ferrando R; Blackmore C; Schroeder K; Rodriguez LA; Hristopoulos M; Venook R; Ashkenazi A; Desnoyers LR
PLoS One; 2012; 7(5):e36713. PubMed ID: 22615798
[TBL] [Abstract][Full Text] [Related]
31. Discovery of 6-Formylpyridyl Urea Derivatives as Potent Reversible-Covalent Fibroblast Growth Factor Receptor 4 Inhibitors with Improved Anti-Hepatocellular Carcinoma Activity.
Yang F; Lin Q; Song X; Huang H; Chen X; Tan J; Li Y; Zhou Y; Tu Z; Du H; Zhang ZM; Ortega R; Lin X; Patterson AV; Smaill JB; Chen Y; Lu X
J Med Chem; 2024 Feb; 67(4):2667-2689. PubMed ID: 38348819
[TBL] [Abstract][Full Text] [Related]
32. EGFR Inhibition Overcomes Resistance to FGFR4 Inhibition and Potentiates FGFR4 Inhibitor Therapy in Hepatocellular Carcinoma.
Shen B; Shi JP; Zhu ZX; He ZD; Liu SY; Shi W; Zhang YX; Ying HY; Wang J; Xu RF; Fang F; Chang HX; Chen Z; Zhang NN
Mol Cancer Ther; 2023 Dec; 22(12):1479-1492. PubMed ID: 37710057
[TBL] [Abstract][Full Text] [Related]
33. FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma.
Huynh H; Prawira A; Le TBU; Vu TC; Hao HX; Huang A; Wang Y; Porta DG
Exp Mol Med; 2020 Nov; 52(11):1857-1868. PubMed ID: 33235319
[TBL] [Abstract][Full Text] [Related]
34. Targeting the FGF19-FGFR4 pathway for cholestatic, metabolic, and cancerous diseases.
Li X; Lu W; Kharitonenkov A; Luo Y
J Intern Med; 2024 Mar; 295(3):292-312. PubMed ID: 38212977
[TBL] [Abstract][Full Text] [Related]
35. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
Yi C; Chen L; Lin Z; Liu L; Shao W; Zhang R; Lin J; Zhang J; Zhu W; Jia H; Qin L; Lu L; Chen J
Hepatology; 2021 Nov; 74(5):2544-2560. PubMed ID: 34036623
[TBL] [Abstract][Full Text] [Related]
36. Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma.
Poh W; Wong W; Ong H; Aung MO; Lim SG; Chua BT; Ho HK
Mol Cancer; 2012 Mar; 11():14. PubMed ID: 22439738
[TBL] [Abstract][Full Text] [Related]
37. Dark and bright side of targeting fibroblast growth factor receptor 4 in the liver.
Gadaleta RM; Moschetta A
J Hepatol; 2021 Dec; 75(6):1440-1451. PubMed ID: 34364916
[TBL] [Abstract][Full Text] [Related]
38. CD146-targeted immunoPET and NIRF Imaging of Hepatocellular Carcinoma with a Dual-Labeled Monoclonal Antibody.
Hernandez R; Sun H; England CG; Valdovinos HF; Ehlerding EB; Barnhart TE; Yang Y; Cai W
Theranostics; 2016; 6(11):1918-33. PubMed ID: 27570560
[TBL] [Abstract][Full Text] [Related]
39. NIR-II fluorescence-guided liver cancer surgery by a small molecular HDAC6 targeting probe.
Wang B; Tang C; Lin E; Jia X; Xie G; Li P; Li D; Yang Q; Guo X; Cao C; Shi X; Zou B; Cai C; Tian J; Hu Z; Li J
EBioMedicine; 2023 Dec; 98():104880. PubMed ID: 38035463
[TBL] [Abstract][Full Text] [Related]
40. Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19.
Zhou M; Wang X; Phung V; Lindhout DA; Mondal K; Hsu JY; Yang H; Humphrey M; Ding X; Arora T; Learned RM; DePaoli AM; Tian H; Ling L
Cancer Res; 2014 Jun; 74(12):3306-16. PubMed ID: 24728076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
